| Literature DB >> 29113471 |
Feng Chen1, Yingxia Liu1, Nai-Kei Wong1, Jia Xiao1,2, Kwok-Fai So3.
Abstract
Stem cell aging is a process in which stem cells progressively lose their ability to self-renew or differentiate, succumb to senescence or apoptosis, and eventually become functionally depleted. Unresolved oxidative stress and concomitant oxidative damages of cellular macromolecules including nucleic acids, proteins, lipids, and carbohydrates have been recognized to contribute to stem cell aging. Excessive production of reactive oxygen species and insufficient cellular antioxidant reserves compromise cell repair and metabolic homeostasis, which serves as a mechanistic switch for a variety of aging-related pathways. Understanding the molecular trigger, regulation, and outcomes of those signaling networks is critical for developing novel therapies for aging-related diseases by targeting stem cell aging. Here we explore the key features of stem cell aging biology, with an emphasis on the roles of oxidative stress in the aging process at the molecular level. As a concept of cytoprotection of stem cells in transplantation, we also discuss how systematic enhancement of endogenous antioxidant capacity before or during graft into tissues can potentially raise the efficacy of clinical therapy. Finally, future directions for elucidating the control of oxidative stress and developing preventive/curative strategies against stem cell aging are discussed.Entities:
Keywords: aging; oxidative stress; signaling pathway; stem cell; transplantation
Mesh:
Substances:
Year: 2017 PMID: 29113471 PMCID: PMC5680960 DOI: 10.1177/0963689717735407
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064
Fig. 1.Aged stem cells are characterized by loss of regenerative function, differentiation, senescence, cell death, and depletion of the functional stem cell pool, which significantly impair their ability to repair damaged tissue.
Fig. 2.Illustration of oxidative stress–evoked signaling pathways in aged stem cells.
Summary of Studies Using Antioxidants to Improve Efficacy of Stem Cell Therapy.
| Disease | Model | Implanted Stem Cell | Antioxidant Treatment | Improvement |
|---|---|---|---|---|
| Myocardial infarction[ | Male mdx mice with cardiotoxin injury | Muscle-derived stem cells (1 × 105 cells) |
| Improves cardiac functions and decreases scar tissue formation |
| Myocardial infarction[ | Male SD rats with left anterior descending coronary artery ligation | Mesenchymal stem cells (2 × 106 cells) |
| Transplantation efficacy was higher in implanted stem cells from young donor rats than that of old donor rats |
| Acute liver failure[ | Male NOD/SCID mice with Gal/LPS challenge | Umbilical cord mesenchymal stem cells, (2 x 10[ | Edaravone | Increases implanted stem cell number, improves hepatic functions, and promotes host liver regeneration |
| Acute interstitial cystitis[ | Male SD rats with cyclophosphamide | Adipose-derived mesenchymal stem cells (1.2 × 106 cells) | Melatonin | Increased stem cell-mediated AIC amelioration through tissue inflammation and oxidative stress regulation |
| Renal ischemia–reperfusion injury[ | Male SD rats with the release of bilateral renal pedicle clamps following occlusion | Bone marrow mesenchymal stem cells (1 × 106 cells) | Atorvastatin | Improves survival of implanted stem cells, enhances injury amelioration outcomes |
| Healthy mice for transplantation efficacy test[ | FVB mice | Adipose-derived mesenchymal stem cells (7 × 105 cells) | Over-expression of endogenous SOD2 expression | Improves survival of grafted cells in early stages after implant. |
| In vitro OH-radical-induced cell damage[ | Cultured cells with FeCl2 (100 μM) followed by H2O2 (50 μM) | Bone marrow mesenchymal stem cells | Dihydromyricetin | Improves cell viability through scavenging O2− and DPPH• radical |
Abbreviations: SOD2, superoxide dismutase 2; AIC, acute interstitial cystitis; DPPH, 1,1-diphenyl-2-picrylhydrazyl; FVB, B strain of the Friend murine leukemia virus; Gal/LPS, D-galactosamine with lipopolysaccharide; NOD/SCID, non-obese diabetic/severe combined immune deficiency; SOD2, superoxide dismutase 2.